Use of ADCs in the Second-Line Treatment of HER2+ mBC
Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.
Sara Hurvitz Melindal Telli Heather Mcarthur Breast Cancer Her2 Breast Cancer Her2 Positive Breast Cancer
Source: onclive.com